Umirolimus

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameUmirolimus
Drug Alias NameNobori (biolimus洗脱支架)A9Ba9AXXESSBioMatrix +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitors
TargetsSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsIschemiaCoronary RestenosisCoronary Artery Disease +[7] 
Global Approved IndicationsCoronary Restenosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2008/04/03
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiosensors International Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiosensors Europe SaFujita Health UniversityWakayama Medical University
Active IndicationsCoronary Restenosis
Inactive IndicationsIschemiaCoronary Artery DiseaseCoronary Disease +[6] 

Other Information

ATC CodeL04AA
Related LinksWikipedia